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Methylated nucleobases : Synthesis and evaluation for base 
pairing in vitro and in vivo 
Amit M. Jabgunde, [a] Faten Jaziri, [b]  Omprakash Bande, [a] Matheus Froeyen, [a] Mikhail Abramov, [a] 
Hoai Nguyen, [a] Guy Schepers, [a] Eveline Lescrinier[a], Vitor B. Pinheiro,[c] Valérie Pezo,[b] Philippe 
Marlière,[b] and Piet Herdewijn*[a] 
Abstract: The synthesis, base pairing properties and in vitro 
(polymerase) and in vivo (E. coli) recognition of 2’-deoxynucleotides 
with a 2-amino-6-methyl-8-oxo-7,8-dihydro-purine (X), a 2-methyl-6-
thiopurine (Y) and a 6-methyl-4-pyrimidone (Z) base moiety are 
described. As demonstrated by Tm measurements, the X and Y bases 
fail to form a self-complementary base pair. Despite this failure, 
enzymatic incorporation experiments show that selected DNA 
polymerases recognize the X nucleotide and incorporate this modified 
nucleotide versus X in the template. In vivo, X is mainly recognized as 
a A/G or C base; Y is recognized as a G or C base and Z is mostly 
recognized as T or C. Replacing functional groups in nucleobases 
normally involved in W-C recognition (6-carbonyl and 2-amino group 
of purine; 6-carbonyl of pyrimidine) readily leads to orthogonality 
(absence of base pairing with natural bases). 
Introduction 
Expanding the genetic alphabet to include an additional base pair 
has led to the replication of such a base pair in a bacterial cell,[1] 
and in the use of such a base pair to code for unnatural amino 
acids.[2] Numerous research groups have studied base modified 
nucleic acids but few of them have been evaluated in vivo.[2-3]  
The candidate base pairs are comprised of reorganized donor–
acceptor hydrogen-bonding groups,[4] increased number of 
hydrogen bonds,[5] size expanded bases,[3b, 6] hydrophobic 
bases,[7] and metal-ion coordinating bases.[8] For example, the 
work of Hirao,[9] and Romesberg,[1-2] demonstrates that 
hydrophobic interactions may contribute to stable base pairing. 
The work of Benner is an example how reorganization of donor-
accepter interactions may lead to orthogonal base pairing in 
vitro.[4c] But many others, likewise, contributed to this research 
field,[10] and this research has been the subject of many 
reviews.[11] 
Introduction of a methyl group in the 5-position of 2’-deoxyuridine 
(giving thymidine) and in the 5-position of 2’-deoxycytidine (giving 
5-methyl-2’-deoxycytidine) increases duplex stability of double
stranded nucleic acids due to hydrophobic interactions with the
neighbouring bases.[12] Here we have replaced functionalities of
purine and pyrimidine bases, normally involved in base pairing,
with a methyl group to investigate the influence on duplex stability
and to investigate the potential to involve them in new base
pairing systems. A second small hydrophobic functionality that is
involved in this study is a thiocarbonyl group (replacing a carbonyl
group), for its potential to interact with the methyl group present
in opposite bases in a duplex. By introducing such methyl and
thiocarbonyl group, we will make the major (or minor groove)
more hydrophobic which may not be favourable for duplex
stabilization and could contribute to orthogonality. However, there
are several precedents of the involvement of a hydrophobic
thiocarbonyl group in base pair stabilization and some natural
tRNA contain sulphur modified nucleobases such as 2-thio-U, 4-
thio-U, 2-thio-C.[13] Rappaport has studied the 6-thioguanine (GS):
5-methyl-2-pyrimidone (TH) base pair (Figure 1a).[14] The
laboratory of  Switzer has investigated the 2-thio-isoguanine
(iGS):5-methyl-isocytosine (iCMe) base pair[15] (Figure 1b) and the
2-thio-isoguanine(iGS):5-methyl-4-pyrimidone (P)[16] base pair
(Figure 1c). In all these cases the thiocarbonyl group was placed
opposite an NH2 group or an H-atom and the stability of the base
pair (GS:TH, iGS:iCMe and iGS:P) was found to be similar to the
canonical A:T pair.
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Figure 1. Schematic representation of putative base pairs between (a) 5-
methyl-2-pyrimidone (TH) with 6-thioguanine (GS) (b) 2-thio-isoguanine (iGS) 
with 5-methyl-isocytosine (iCMe) (c) 2-thio-isoguanine (iGS) with 5-methyl-4-
pyrimidone (P) (d) 6-methyl-4-pyrimidone (Z) with 2-methyl-6-thiopurine (Y) (e) 
self-base pair of 2-methyl-6-thiopurine (Y:Y), (f) 2-amino-6-methyl-8-oxo-7,8-
dihydro-purine (X) and 6-methyl-4-pyrimidone (Z) 
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The use of a self-complementary base for the expansion of the 
genetic alphabet has the advantage that the potential for 
mispairing with the natural bases is reduced (as only one base 
has to be considered for mispairing). It is not really a limitation 
since the addition of a single self-complementary base to the 
genetic alphabet would create 61 new codons. For example 
Pochet and Marlière[17] proposed a self-pair using a 2-amino-8-
oxo-7,8-dihydro-purine base, with the potential to form two 
hydrogen bonds (Figure 2a). This work is based on the well-
recognized ability of the mutagenic 8-oxoguanine to base pair with 
adenine base, the former oriented in the syn conformation. This 
8-oxoG (syn):A(anti) base pair was studied by X-ray diffraction
and NMR[18]
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Figure 2. Schematic representation of a putative self−complementary base pair 
of (a) 2-amino-8-oxo-7,8-dihydro-purine (b) 2-amino-6-methyl-8-oxo-7,8-
dihydro-purine (X). 
Replacement of G with 8-oxoG increases thermal stability of 
duplex when A is placed in the opposite position.[19] The presence 
of the 8-oxo group induces glycosidic bond rotation which led to 
8-oxoG(syn):A(anti) conformation.[18b] When 2-amino-8-oxo-7,8-
dihydro-purine is placed opposite to A, thermal stability of the
duplexes (compared with A:T) is decreased.[20] However, 2-
amino-8-oxo-7,8-dihydro-purine:2-amino-8-oxo-7,8-dihydro-
purine self-pair showed less destabilization. The relative stability
of the 2-amino-8-oxo-7,8-dihydro-purine self-pair could be
explained by the formation of two hydrogen bonds (Figure 2a).
A first example that we investigated is the potential self-
complimentary base pair 2-amino-6-methyl-8-oxo-7,8-dihydro-
purine (X) (Figure 2b) in the syn:anti conformation.
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Figure 3. 2’-Deoxyribonucleosides, with modified purine (X and Y) and 
pyrimidine (Z) bases that have been used in this study. For the sake of simplicity, 
we use X, Y and Z as code, as well for the base as for the nucleos(t)ide. 
Further, we have included in our study the 2-methyl-6-thiopurine 
base (Y) to pair with the 6-methyl-4-pyrimidone heterocycle 
(Figure 1d) (Z) and with itself (Figure 1e). In addition, potential 
pairing of the modified pyrimidone heterocycle (Z) with the 
previously mentioned 2-amino-6-methyl-8-oxo-7,8-dihydro-purine 
base (X) was investigated (Figure 1f). 
There are many precedents in the literature of the stabilization of 
macromolecular structure or small molecule interactions by 
thiocarbonyl and methyl groups.[21] In addition the higher 
polarizability of sulphur over oxygen may contribute to enhanced 
stacking interactions.[22]
Our investigation started by building a static in silico model to 
analyse if X:X interactions and Z:Y interactions are potentially 
accessible in a dsDNA context. The models are shown in Figures 
4 and 5. Although distances between functional groups are not 
optimal, closer contacts are possible in the pyrimidine:purine 
system (Figure 5) than in the purine self-pair system (Figure 4). 
The 6-methyl-4-pyrimidone nucleoside was modelled in the trans 
configuration, while the presence of the 4-carbonyl group would 
suggest that the cis configuration is more stable. The models 
demonstrate that, in theory, accommodation of both base pairs in 
a dsDNA structure might be possible. 
Figure 4. Static model showing potential base:base interactions in a 2-amino -
6-methyl-8-oxo-7,8-dihydro-purine (X) self-pair. Ac
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Figure 5. Static model showing potential base:base interactions in the 6-methyl-
4-pyrimidone (Z) and 2-methyl-6-thiopurine (Y) base pair. 
Result and discussion 
The 2-chloro-4-amino-5-nitro-6-methyl pyrimidine 2 was 
synthesized according to a reported procedure with minor 
modifications.[23] The nitro group of 2 was reduced using sodium 
hydrosulphite to afford 2-chloro-4,5-diamino-6-methyl pyrimidine 
3. Reaction of 2-chloro-4,5-diamino-6-methyl- pyrimidine 3 with
1,1’-carbonyldiimidazole in 1,4-dioxane at 110 °C afforded
compound 4.
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Scheme 1. Synthesis of 2-chloro-6-methyl-8-oxo-7,8-dihydro-purine 
nucleoside. (a) Na2S2O4, H2O:EtOAc:THF  (1:1:3.5), rt, 3h, 39% (b) 1,1'-
carbonyldiimidazole, 1,4-dioxane, 110 °C, 50 min, 86% (c) NaH, 1-chloro-2-
deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranose, 50 °C, 3h, 30%; (d) 
NaOMe, MeOH, rt 1h, 95%; (e) DMTrCl, pyridine, 0 °C to rt, 12 h, 58%  β isomer; 
(f) 1.25 M HCl, MeOH:CH2Cl2 (1:1). 
The sodium salt of 4, produced in situ using NaH in acetonitrile 
was reacted with 1-chloro-2-deoxy-3,5-di-O-p-toluoyl-α-D-
erythro-pentofuranose at 50 °C. The reaction mixture was purified 
on silica gel column to afford 2-chloro-6-methyl-8-oxo-7,8-
dihydro-9-(2-deoxy-3,5-di-O-p-toluoyl-D-erythro-pentofuranos-1-
yl)-purine (5) as an inseparable mixture of α and β-anomer in 30% 
yield. Treatment of 5 with sodium methoxide in methanol 
deprotected the toluoyl groups. The crude product was then 
purified by flash column chromatography to yield an inseparable 
anomeric mixture of 6 as a white solid. Compound 6 was 
converted to its dimethoxytrityl derivative 7 by selective protection 
of the primary alcohol with 4,4’-dimethoxytrityl chloride (DMTrCl) 
in pyridine. Flash column chromatography was used to separate 
the desired β-isomer from the α-isomer and ROESY and HMBC 
of 2D NMR was used to prove the correct structure. Trityl 
deprotection of compound 7 afforded the nucleoside 8. 2D NMR 
analysis of compound 8 confirmed the previous structural 
analysis. However, amination of 2-chloro of compound 6 using 
ammonia under heating conditions was unsuccessful. Therefore, 
we decided to replace first the 2-chloro by a 2-azido group, and 
to separate the isomers after introduction of the 2-amino function. 
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Scheme 2. Synthesis of the protected phosphoramidite of 2-amino-6-methyl-8-
oxo-7,8-dihydro-9-(2-deoxy-β-D-erythro-pentofuranos-1-yl)-purine. (a) NH2-
NH2, EtOH, 84 °C, 12 h; (b) NaNO2, AcOH, −5 °C - rt, 12 h; (c) H2, PtO2, MeOH, 
55 °C, 45 h, 21% over 3 steps; (d) DMF–DMA, MeOH, rt, 1 h; (e) DMTrCl, 
pyridine, 0 °C to rt, 12 h, 58% β anomer; (f) (i-Pr2N)2POC2H4CN, 1H-tetrazole, 
CH2Cl2, 0 °C to rt, 1 h, 64%. 
Thus, nucleoside 6 was treated with hydrazine in ethanol to afford 
the 2-hydrazino derivative 9 which on further reaction with nitrous 
acid at −5 °C, led to formation of 2-azido-6-methyl-8-oxo-7,8-
dihydro-purine nucleoside 10. Reduction of azido group followed 
by N,N-dimethylaminomethylidene protection of the resulting 
amine function afforded  compound 12 which, upon tritylation, 
gave a separable mixture of the α,β-anomers 13. The desired β-
anomer was isolated by flash column chromatography and 
converted into phosphoramidite 14 by reaction with 
bis(diisopropylamino)(2-cyanoethoxy)phosphine in the presence 
of tetrazole. 
The triphosphate (of compound β-12) was synthesized according 
to the method described by Ludwig[24] starting from corresponding 
N,N-dimethylaminomethylidene protected nucleoside β-12 
(obtained by detritylation of compound 13) (Scheme 3). In this 
procedure, regioselective phosphorylation of the 5’-hydroxy group 
of the sugar moiety was carried out with phosphoryl oxychloride 
in trimethyl phosphate followed by the addition of 
tetrabutylammonium pyrophosphate. The reaction product was 
deprotected with aqueous ammonia, isolated on Sephadex A25 
column and final purification was performed by RP HPLC. 
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Scheme 3. Synthesis of the triphosphate 15 a) 1% TFA on Silica column b) i) 
trimethylphosphate, POCl3, 0°C, 5 h; ii) Bu3N, (NBu4)3HP2O5, 30 min; iii) 25% 
NH3, 2 h; 
As depicted in scheme 4, glycosylation of commercially available 
6-methyl-4-pyrimidone with 3,5-bis-(toluoyl)-2-deoxyribosyl
chloride using bis(trimethylsilyl)acetamide and SnCl4 in dry
acetonitrile afforded a crude mixture of 6-methyl-4-pyrimidone
nucleoside. The cleavage of toluoyl-protecting group was carried
out using 5 M solution of sodium methoxide in methanol to afford
pure 6-methyl-3-(2-deoxy-β-D-erythro-pentofuranos-1-yl)-4-
pyrimidone Z in 36% yield over two steps. Selective protection of
the primary alcohol with 4,4’-dimethoxytrityl chloride (DMTrCl) in
pyridine gave 16, which was then converted to phosphoramidite
17 by reaction with bis(diisopropylamino)(2-cyanoethoxy)
phosphine in the presence of tetrazole.
O
OTol
Cl
TolO
N
H
N
CH3
O
O
OTol
TolO N
N
CH3
O
O
OH
HO N
N
CH3
O
O
OH
DMTrO N
N
CH3
O
O
O
DMTrO N
N
CH3
O
P
O
N
CN
a b c
d
Z
16 17
Scheme 4. Synthesis of the protected phosphoramidite of 6-methyl-3-(2-deoxy-
5-O-DMTr-β-D-erythro-pentofuranos-1-yl)-4-pyrimidone. (a) SnCl4, BSA,
CH3CN, rt, 2 h; (b) NaOMe, MeOH, 1.5 h, rt; (c) DMTrCl, pyridine, 0 °C to rt, 12
h, 69 %; (d) bis-(diisopropylamino)(2-cyanoethoxy)-phosphine, tetrazole,
CH2Cl2, 0 °C to rt, 2.5 h, 62%. 
The sodium salt of 2-methyl-6-chloropurine, produced in situ 
using NaH in acetonitrile, was reacted with l-chloro-2-deoxy-3,5-
di-O-p-toluoyl-α-D-erythro-pentofuranose at room temperature to
afford the desired nucleoside 18a in 76% yield (Scheme 5). The
6-chloro group in 18a was converted into a thiol group by
treatment with sodium thiosulfate. Cleavage of toluoyl protecting
groups by a 5 M solution of sodium methoxide in methanol
(compound Y) followed by reaction with 3-bromopropionitrile in
presence of potassium carbonate gave compound 19. Selective
protection of the primary alcohol with 4,4’-dimethoxytrityl chloride
(DMTrCl) in pyridine gave 20, which was then converted to its
phosphoramidite 21 by reaction with bis(diisopropylamino) (2-
cyanoethoxy)phosphine in the presence of tetrazole. 
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Scheme 5.  Synthesis of the protected phosphoramidite of 2-methyl-6-thio-9-
(2-deoxy-β-D-erythro-pentofuranos-1-yl)-purine. (a) NaH, 1-chloro-2-deoxy-3,5-
di-O-p-toluoyl-α-D-erythro-pentofuranose, CH3CN, rt, 2 h, 76 %; (b) Na2S2O3, 
EtOH-H2O, 120 °C, 12 h, 80%. (c) NaOMe, MeOH, 1.5 h, rt, 78%; (d) 3-
bromopropionitrile, K2CO3, DMF, rt, 80%; (e) DMTrCl, pyridine, 0 °C to rt, 12 h,
75 %; (f) bis(diisopropylamino)(2-cyanoethoxy)phosphine, tetrazole, CH2Cl2, 0
°C to rt, 2.5 h, 68 %. 
Hybridization properties of XNA modified DNA 
The oligonucleotides were synthesized by using the 
phosphoramidite method and the reagents 14, 17 and 21 on solid 
phase employing a DNA synthesizer. The synthesized sequences, 
together with the MS data, are shown in Table 1. The 
oligonucleotides ON 20-23 were used as well for Tm studies as for 
in vivo transliteration experiments.  
Base pairing properties of the X, Y and Z bases were examined 
by hybridizing oligomers with their complementary strands and 
determining the Tm of the hybrids by temperature-dependent UV 
spectroscopy. The Tm was determined at 260 nm in NaCl (0.1M) 
buffer with KH2PO4 (20 mM, pH 7.5) and EDTA (0.1 mM) at a 
concentration of 4 µM for each strand. The stability of the 
duplexes containing the modified bases (X, Y, Z) was compared 
to the stability of the natural DNA duplex (Table 2). Ac
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Table 1. DNA sequences with X, Y and Z modified bases that have been 
synthesized, together with the MS data. 
ON Sequence Mass Mass 
1 5’-CAC CGX TGC TAC C-3’ 3907.7 3907.7 
2 5’-GGT AGC AXC GGT G-3’ 4067.7 4067.9 
3 5’-CAC CGY TGC TAC C-3’ 3908.7 3908.5 
4 5’-GGT AGC AYC GGT G-3’ 4068.7 4068.7 
5 5’-GGT AGC AZC GGT G-3’ 4012.7 4012.8 
6 5’-d GCG CXX GCG C-3’ 3096.6 3096.7 
7 5’-GXG CAT GCX C-3’ 3095.6 3095.6 
8 5’-CTA GCX CCG TGC CAT GCA-3’ 5472.0 5472.1 
9 5’-p- TGC ATG GCA CGG XGC TAG-3’ 5671.9 5671.8 
10 5’-CTA GCX CXG TGC CAT GCA-3’ 5526.0 5526.2 
11 5’-p-TGC ATG GCA CXG XGC TAG-3’ 5686.0 5685.9 
12 5’-CTA GCX XCG TGC CAT GCA-3’ 5526.0 5526.2 
13 5’-p-TGC ATG GCA CGX XGC TAG-3’ 5686.0 5685.9 
14 5’-CTA GCX XXG TGC CAT GCA-3’ 5580.0 5580.1 
15 5’-p TGC ATG GCA CXX XGC TAG-3’ 5700.0 5699.9 
16 5’-p-CTA GCX CCG TGC CAT GCA-3’ 5551,9 5552,2 
17 5’-p-CTA GCX CXG TGC CAT GCA-3’ 5605,9 5606,2 
18 5’-p-CTA GCX XCG TGC CAT GCA-3’ 5605,9 5606,2 
19 5’-p-CTA GCX XXG TGC CAT GCA-3’ 5660,0 5660,3 
20 5’-p-CTA GCY CCG TGC CAT GCA-3’ 5552.9 5552.8 
21 5’-p-CTA GCY CYG TGC CAT GCA-3’ 5607.9 5607.9 
22 5’-p-CTA GCY YCG TGC CAT GCA-3’ 5607.9 5608.0 
23 5’-p-CTA GCY YYG TGC CAT GCA-3’ 5662.9 5663.0 
24 5’-p-CTA GCZ CCG TGC CAT GCA-3’ 5496.9 5496.9 
25 5’-p-CTA GCZ CZG TGC CAT GCA-3’ 5495.9 5496.0 
26 5’-p-CTA GCZ ZCG TGC CAT GCA-3’ 5495.9 5496.2 
27 5’-p-CTA GCZ ZZG TGC CAT GCA-3’ 5494.9 5495.0 
28 5’-p-TGC ATG GCA CGG ZGC TAG-3’ 5616.9 5617.0 
29 5’-p-TGC ATG GCA CZG ZGC TAG-3’ 5575.9 5576.0 
30 5’-p-TGC ATG GCA CGZ ZGC TAG-3’ 5575.9 5576.1 
31 5’-p-TGC ATG GCA CZZ ZGC TAG-3’ 5534.9 5535.2 
32 5’-AAC TGX GTC ATA GCT GTT TCC TG-3’ 7059.5 7058.8 
33 5’-AAC TGX XXG TCA TAG CTG TTT CCT G-3’ 7745.7 7745.0 
Table 2. Tm values (in °C) of antiparallel stranded DNA oligonucleotide duplexes 
A:, 5’-CAC CG1 TGC TAC C-3’ and B:, 3’-GTG GC2 ACG ATG G-5’ containing 
A, T, C, G bases and the modified base pairs X:X, Y:Y, Y:Z and X:Z. 
Sequence A 1 A T C G X Y Y X 
Sequence B 2 T A G C X Y Z Z 
Duplex Tm (°C) 57.5 57.3 61.3 59.7 45.2 41.7 47.3 46.6 
From this table it is clear that the potential base pairing between 
the modified bases X:X, Y:Y, Y:Z and X:Z are very week, if they 
exist at all  (certainly for Y:Y). For example, the pyrimidone 
nucleoside Z is not expected to occur in the conformation as 
proposed in Figure 1d. However, the stability Z:X and Z:Y is about 
the same. The Tm of the duplex is decreased with at least 10 °C 
when compared with the Tm of the canonical base pairs. This 
could be due to the difficulty of X, Y and Z to adopt a high energy 
syn or anti conformation within the duplex or due to steric 
hindrance. The Tm of duplexes with a modified pyrimidine, 
modified purine base pair (Y:Z and X:Z) is higher than the Tm of 
duplexes with a potential modified self-complementary purine 
base pair (X:X and Y:Y), respecting shape-recognition rules, and 
the difficulty for the simultaneous orientation of the X and Y 
modified purine bases in the syn and anti conformation. Steric 
clash between the hydrophobic substituent within the potential 
X:X and Y:Y base pair (despite the encouraging modeling data) 
may further explain these results. 
In order to investigate the selectivity of base pairing, the stability 
of duplexes with modified X, Y, Z bases and the four canonical 
bases (A, T, G, C) was investigated by Tm determination (Table 
3). In all cases, the potential base interactions are weak, 
especially with the Z base. The potential base pairing with the 
canonical bases is, in general, somewhat better than the potential 
X:X and Y:Y self-pairing. The highest Tm in this series is found for 
Y:A, which might be due to syn:anti interactions (Figure 6). 
N
NH
S
CH3
N
N
N
NH2N
N
N
H
dR
Y (anti)
dR
A (syn)
Figure 6. Potential base pairing between the 2-methyl-6-thiopurine base (Y) 
and adenine (A) in the Y (anti): A (syn) conformation.  
As the strength of duplex formation is not only the result of 
potential interstrand base:base interactions by H-bonding but also 
due to potential base:base interactions by interstrand stacking, 
we have evaluated the X:X and the Y:Z system further by 
incorporating several modified X, Y and Z bases in a dsDNA, 
either separately or consecutively (Table 4). One of the 
sequences is phosphorylated at the 5’-position, because this 
sequence was also used for insertion in a plasmid for the in vivo 
experiments. The Tm data shows that multiple incorporations 
further reduced duplex stability in comparison to dsDNA reference 
duplex (Tm = 72.9 °C). 
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Table 3. Tm values (in °C) of antiparallel stranded DNA oligonucleotide duplexes 
containing A, T, C, G bases and the modified bases X, Y, Z. 
Table 4. Tm values (in °C) of antiparallel stranded DNA oligonucleotide duplexes 
with single and multiple X, Y and Z incorporated. 
Sequence Tm (°C) Sequence 
Tm 
(°C) 
5’-P-TGC ATG GCA CGG XGC 
TAG-3’ 
3’-    ACG TAC CGT GCC XCG 
ATC-5’ 
61.7 
5’-p-CTA GCY CCG TGC CAT 
GCA-3’ 
3’-GAT CGZ GGC ACG  
GTA CGT-p-5’ 
63.2 
5’-P-TGC ATG GCA CXG XGC 
TAG-3’ 
3’-    ACG TAC CGT GXC XCG 
ATC-5’ 
51.3 
5’-p-CTA GCY CYG TGC CAT 
GCA-3’ 
3’-GAT CGZ GZC ACG  
GTA CGT-p-5’ 
54.0 
5’-P-TGC ATG GCA CGX XGC 
TAG-3’ 
3’-    ACG TAC CGT GCX XCG 
ATC-5’ 
54.7 
5’-p-CTA GCY YCG TGC CAT 
GCA-3’ 
3’-GAT CGZ ZGC ACG  
GTA CGT-p-5’ 
55.7 
5’-P-TGC ATG GCA CXX XGC 
TAG-3’ 
3’-    ACG TAC CGT GXX XCG 
ATC-5’ 
49.0 
5’-p-CTA GCY YYG TGC CAT 
GCA-3’ 
3’-GAT CGZ ZZC ACG  
GTA CGT-p-5’ 
48.8 
Finally, we carried out three additional experiments to further 
analyze the properties of the 2-amino-6-methyl-8-oxo-7,8-
dihydropurine (X) base: a) the potential of the X base to induce 
hairpin formation; b) a CD experiment to compare the shape of 
natural dsDNA with the “X incorporated” dsDNA; c) the potential 
of the triphosphate of the X nucleoside to function as substrate for 
DNA polymerases. 
The 2-amino-6-methyl-8-oxo-7,8-dihydro-purine nucleosides X 
was incorporated in the self-complementary 5’-GCG CAT GCG-
C-3’ DNA sequence as well at the second position from both ends 
as in the middle positions and the Tm was measured at different 
concentrations ranging from 2 µM to 12 µM in 1N NaCl at 286 nm 
(Table 5). When positioning X at both ends, the oligonucleotide 
remains in a self-complementary duplex just as the natural 
sequence, although with considerably reduced Tm. However, 
positioning XX in the middle of the oligonucleotide, force it to 
adopt a hairpin conformation. This is in agreement with former 
observations that the X:X base pair is not really formed. 
Table 5. Concentration dependent Tm of DNA after positioning X at different 
place. 
Sequence 2 µM 4 µM 6 µM 8 µM 12 µM Conformation 
5’-GCG CXX GCG C-3’ 64.9 64.6 64.5 64.1 64.5 Hairpin 
5’-GXG CAT GCX C-3’ 27.7 29.0 31.3 36.0 37.8 Duplex 
5’-GCG CAT GCG C-3’ 52.6 59.6 60.1 62.3 63.8 Duplex 
Figure 7. CD spectra of oligonucleotide duplexes. The ellipticity is plotted 
versus the wavelength for 2-amino-6-methyl-8-oxo-7,8-dihydro purine (dash 
dotted green line) and 2-methyl-6-thiopurine (dashed blue line) containing 
oligonucleotides along with control sequences with natural base (solid red line). 
Sequence: 5’-CACCGX/YTGCTAC-C-3’ and its complement I 5’-GCTAGCAX/Y 
CGGTG-3’. In the reference duplex, the base pair in the position of X/Y is A/T. 
Figure 7 shows the CD spectra of dsDNA with a single X:X and 
Y:Y base pair incorporated in the middle of the sequence. All 
duplexes have CD spectra indicative of right-handed B-DNA, with 
small variation in peak position and ellipticity. The spectra for the 
natural DNA sequence exhibit broad negative peak at 252 nm and 
positive long wavelength peak at about 272 nm, typical of right 
handed B-DNA. The spectra for sequences with 2-amino-6-
methyl-8-oxo-7,8-dihydro-purine X and 2-methyl-6-thiopurine Y 
resemble each other but show some deviation in peak position 
and ellipticity from the spectra of natural dsDNA.
Sequence Tm 
(°C) 
Sequence Tm 
(°C) 
5’-CAC CGX TGC TAC C-3’ 5’-CAC CGY TGC TAC C-3’ 
3’-GTG GCT ACG ATG G-5’ 49.1 3’-GTG GCT ACG ATG G-3’ 50.8 
3’-GTG GCA ACG ATG G-5’ 48.2 3’-GTG GCA ACG ATG G-3’ 51.1 
3’-GTG GCG ACG ATG G-5’ 47.7 3’-GTG GCG ACG ATG G-3’ 47.8 
3’-GTG GCC ACG ATG G-5’ 47.2 3’-GTG GCC ACG ATG G-3’ 44.7 
5’-GGT AGC AXC GGT G-3’ 5’-GGT AGC AZC GGT G-3’ 
3’-CCA TCG TTG CCA C-5’ 49.3 3’-CCA TCG TTG CCA C-3’ 43.7 
3’-CCA TCG TAG CCA C-5’ 49.0 3’-CCA TCG TAG CCA C-5’ 45.6 
3’-CCA TCG TGG CCA C-5’ 48.9 3’-CCA TCG TGG CCA C-5’ 48.3 
3’-CCA TCG TCG CCA C-5’ 49.4 3’-CCA TCG TCG CCA C-5’ 42.0 
Ac
ce
pt
ed
 A
rti
cl
e
10.1002/chem.201802304
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
FULL PAPER 
Figure 8. Polymerase catalysed incorporation of dNTP’s and nucleotide 15 in a DNA primer-template complex. 
The spectra shows a more narrow negative peak at 255 nm and 
positive peak at 276 nm with reduced height.  The introduction of 
modified self–complementary base pair with hydrophobic groups 
not only destabilizes the DNA duplex but also results in small 
conformational changes. 
The enzymatic incorporation of the modified X nucleotides in DNA 
was tested using Klenow (exo-) and Pol6G12. The Klenow 
fragment was chosen because of its potential relevance for in vivo 
work in E. coli. The Pol6G12, an evolved enzyme derived from 
the thermophilic archaebacterium Thermococcus gorgonarius, 
was chosen because of its potential relevance for in vitro work 
(XNA gene synthesis and aptamer). First the triphosphate of the 
2-amino-6-methyl-8-oxo-7,8-dihydro-9-(2-deoxy-β-D-erythro-
pentofuranos-1-yl)-purine nucleoside was synthesized (15,
Scheme 3). The incorporation of natural dNTP’s and the modified
nucleotide X was compared using a template with one and three
nucleotides incorporated (see experimental section) and a DNA
primer. Using Klenow polymerase in the absence of Mn2+ little X
is incorporated against X in the template (Figure 8). Using Klenow 
polymerase in the presence of Mn2+, the incorporation efficiency
significantly increases (Figure 8). Data are similar for 50 µM and
200 µM of the modified nucleotide and using a template with one
or three modified bases. In Figure 8, only data with one modified
base in the template is shown. Similar results are observed using
Pol6G12. In the presence of Mn2+, the modified nucleotide X is
incorporated against X in the template, although from previous
experiments we know that X:X does not form a stable base pair,
in vitro. We would also like to exclude that incorporation is due to
a template-independent synthesis. In the presence of Mn2+ no
template-independent synthesis is observed using Klenow
polymerase (Figure 8). However, some template-independent
synthesis is observed using Pol6G12 polymerase (although less
than in the presence of the template).
Recognition of modified bases in vivo 
In search for new orthogonal base pairs in vivo, it is important to 
know “if and how” the modified bases are functioning as template 
for canonical bases in vivo in the presence of cellular 
polymerases. To test the propagation of the XNA bases in vivo, 
the three bases were introduced separately (by chemical 
synthesis) in a sequence 5’-CTA GCG CCG TGC CAT GCA-3’ 
representing the active site of thymidylate synthase (thyA) of E. 
coli (coding for Leu – Ala – Pro – Cys – His – Ala). They were 
introduced in the GCG codon (coding for Ala) and in the CCG 
codon (coding for Pro) (Table 6). 
Table 6 Sequence of the synthesized oligonucleotides representing the active 
site of thyA of E. coli indicating the different positions () in which the modified 
bases (X, Y, Z) were introduced. 
Code Leu Ala Pro Cys His Ala 
ON 16, 20, 24 5’-p- CTA GC CCG TGC CAT GCA -3’
ON 17, 21, 25 5’-p- CTA GC CG TGC CAT GCA -3’
ON 18, 22, 26 5’-p- CTA GC CG TGC CAT GCA -3’
ON 19, 23, 27 5’-p- CTA GC G TGC CAT GCA -3’
These oligonucleotides were ligated enzymatically in a gapped 
vector, transformed in a strain of E. coli (lacking thyA) and living 
colonies were analyzed (ratio between bacterial colony numbers 
in ± thymidine (dT) media). Only in case a productive DNA 
polymerase ternary complex is obtained with the unnatural 
nucleotide and a tolerated amino acid substitution is coded by the 
targeted codon, living colonies are obtained (as thyA in an 
essential enzyme in E. coli). Sequencing gives us information as 
which canonical base the modified bases recognize and which 
amino acids are inserted in the active protein. In each case, 20 
clones were picked out in the dT deficient media and sequenced. 
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As shown in Figure 9, all three bases are very poorly recognized 
in vivo, when compared with the positive control. Even after 
introduction of only one base, the efficiency of transliteration of 
XNA to DNA is reduced to approximately 10 % in all cases. This 
percentage is further reduced between 0 % to 2 % when 
introducing two or three modified bases. When bars are not visible 
(Figure 9), only 1 or 2 colonies could be obtained, except for Y (2-
methyl-6-thiopurine), inserted in GC() C()G, where no colony 
was obtained. These modified bases come close to the definition 
of orthogonal bases. 
2-Amino-6-methyl-8-oxo-7,8-dihydro-purine, when introduced as
third base in the Ala codon GCG (GCX) is recognized as a purine
base (84 % as GCG and 16 % as GCA) (Table 7). Both triplets
code for the amino acid “Ala”. When 2-amino-6-methyl-8-oxo-7,8-
dihydro-purine base is introduced as first or second base in the
Pro codon (XCG and CXG), it is always (100 %) recognized as a
cytosine base (CCG and CCG), coding for Pro (Table 8). This
could be explained by X is recognized by G in a Wobble-
Hoogsteen type association. These data are obtained using ON
17 and ON 18 where X is also incorporated in the Ala codon which
might give some bias for base incorporation, especially for XCG
(ON 18) It should be mentioned that not only CCG (coding for Pro) 
but also TCG (coding for Ser), GCG (coding for Ala) and CGG
(coding for Arg) are tolerated at this position of the ThyA gene.
However, we cannot conclude on the real impact of the individual
amino acid substitutions on the enzyme efficiency. This
observation is of interest as it shows that selection pressure
(invariably Ala-Pro is selected) in this case is higher than
structural constrains. The modified base can behave either as a
purine or either as a pyrimidine analogue in vivo dependent on
the place where it is inserted in the gene. Needless to say that
there is no correlation with the results obtained by thermal stability
experiment of the modified oligonucleotides (see previous), where 
hybridization of 2-amino-6-methyl-8-oxo-7,8-dihydro-purine X
with A,G,C,T is very poor, if existing at all, and similar for all 4
canonical bases. Clearly, E.coli DNA polymerases have a key role 
in the selection procedure via stabilization of the protein-dsDNA-
dNTP ternary complex.
The 2-methyl-6-thiopurine base Y, when incorporated in the GCG
(Ala) codon at the third position (GCY) is recognized almost
exclusively (99 %) as a G (GCG) and in 1 % of the cases as a T
(GCT) (Table 7). Both triplets code for Ala. When an extra
modified base is introduced in the CCG (Pro) codon at the first
position (YCG), it is recognized for 93 % as G base (GCG) coding
for Ala and for 7 % as C base (CCG) coding for Pro (Table 8).
When 2-methyl-6-thiopurine base is incorporated in the second
position of the same codon (CYG) it is recognized as a cytosine
base (CCG) in 100 % of the cases (Table 8). When introduced as
well in the first as the second position (ON 23) of this CCG code
(YYG), the codon only codes for Ala giving GCG as codon, and
not anymore for Pro (data not shown in Table 8). It thus seems
that the presence of one modified base in a codon may influence
the recognition pattern of a second modified base, introduced in
the same codon. Structural constrains seem more challenging
than the selection pressure which leads to the high substitution of
Pro by Ala (93 %). It should be remembered, of course, that only
viable codons can be detected which is a bias of the analytical
system (the obtained results are steered by the kind of amino 
acids that are accepted at a certain position in the protein). In the 
Ala codon (GCY), however, this does not make a difference as all 
four possible codons (GCA, GCT, GCC, GCG) lead to the 
incorporation of Ala at this site of the protein (still a bias may exist 
based on the preferential use of E. coli for certain codons). 
Finally, the 6-methyl-4-pyrimidone nucleoside Z was analysed in 
vivo, which gives a more complicated profile. In the Ala codon 
(GCZ), the 6-methyl-4-pyrimidone base is mainly recognized as a 
pyrimidine base (75 % as the T giving GCT, and 17 % as C giving 
GCC) and as G base to a minor extend (8 % as GCG) (Table 7). 
When introduced in the first position of the CCG code (ZCG) we 
find equal amounts of the TCG code (Ser) and CCG code (Pro) 
which means that 6-methyl-4-pyrimidone behaves as a pyrimidine 
base and the Ser substitution is well tolerated in thymidylate 
synthase (Table 8). The same amino acids (Ser and Pro) are 
coded for when the modified base is introduced at the first and 
second position (ZZG). When introduced only at the second 
position (CZG), the pyrimidone base is still recognized in majority 
as pyrimidine base (CCG), but also as G base in minority (CGG) 
coding for Arg. When three modified bases are introduced in a 
row (GCZ  ZZG), 58 % of Ala-Ser is introduced (GCT TCG) and 
42 % of Ala-Pro (17 % GCG CCG, 17 % GCC CCG, 8 % GCT 
CCG) (data not shown in Table 8). 
It is difficult to make general statements about the preferred 
recognition of modified purine and modified pyrimidine bases at 
this moment. Shape recognition (purine-pyrimidine base pair 
formation) is, however, important. The Z base is recognized as a 
pyrimidine in 90% of the cases (and only in 8-10% as a purine). 
Transversions coming from a purine-purine base pair are 
observed in relatively high yield with the X and Y base, probably 
because of the syn-anti equilibrium that may convert a purine to a 
pyrimidine-like base. 
Table 7 - In vivo recognition of modified bases by canonical bases in the GCG 
(Ala) codon (aa: amino acid) 
5’- CTA GC CCG TGC CAT GCA-3’ 
 Leu  aa  Pro  Cys  His  Ala 
aa X (%) Y (%) Z (%) 
A Ala 16 0 0 
T Ala 0 1 75 
C Ala 0 0 17 
G Ala 84 99 8 
X  2-amino-6-methyl-8-oxo-7,8-dihydro-purine 
Y  2-methyl-6-thio-purine 
Z  6-methyl-4-pyrimidone 
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Table 8 - In vivo recognition of modified bases by canonical bases in the GCG 
(Pro) codon (aa: amino acid) 
 5’-GTA GC CG TGC CAT GCA-3’ 
      Leu   Ala     aa    Cys   His   Ala 
5’-CTA GC CG TGC CAT GCA-3’ 
     Leu   Ala    aa    Cys   His   Ala 
CG   CG 
aa X 
(%) 
Y 
(%) 
Z 
(%) 
aa X (%) Y (%) Z (%) 
A Thr 0 0 0 Glu 0 0 0 
T Ser 0 0 50 Leu 0 0 0 
C Pro 100 7 50 Pro 100 100 90 
G Ala 0 93 0 Arg 0 0 10 
X  2-amino-6-methyl-8-oxo-7,8-dihydro-purine 
Y  2-methyl-6-thio-purine 
Z  6-methyl-pyrimidone 
Figure 9. The in vivo propagation of the mosaïc DNA-XNA-DNA 
oligonucleotides. 2-amino-6-methyl-8-oxo-7,8-dihydro-purine modified 
oligonucleotides are represented in blue, 2-methyl-6-thio-purine modified 
oligonucleotides are represented in red and 6-methyl-4-pyrimidone modified 
oligonucleotides are represented in green. Ratios are normalized against 
positive control (100%) and correspond to the experimentally derived number 
of thymidine-prototrophic colonies (thyA+) from the total number of colonies. 
Conclusions 
An efficient synthetic scheme was developed for the synthesis of 
the protected phosphoramidites of 2’-deoxynucleosides with a 2-
amino-6-methyl-8-oxo-7,8-dihydro-purine (X), a 2-methyl-6-
thiopurine (Y) and a 6-methyl-4-pyrimidone (Z) base moiety. 
These building blocks were successfully used for oligonucleotide 
synthesis. These modified bases do not form base pairs with itself 
(X:X and Y:Y) and with the natural bases (A, G, C, T). Substitution 
of a polar functional group (NH2, OH) of nucleobases by a methyl 
group at positions that are normally involved in H-bonding of 
canonical bases (the 6-carbonyl group of pyrimidine base, the 2-
amino and 6-carbonyl group of purine base) readily leads to 
orthogonality (absence of base pairing with canonical bases). As 
demonstrated with the TH:GS base pair[16] base pairing between 
methylated bases or bases with a thiocarbonyl group might easier 
occur when a H-atom is present in the opposite base (Figure 1c). 
However, the latter bases might not be really orthogonal. 
Surprisingly, some selected polymerases are still able to 
incorporate the 2-amino-6-methyl-8-oxo-7,8-dihydro-purine 
nucleoside opposite itself in a template. In vivo, 2-amino-6-
methyl-8-oxo-7,8-dihydro-purine is mainly recognized as a A/G or 
C base. 2-Methyl-6-thio-purine is recognized as a G or C base 
(and in a minor case as T base). 6-Methyl-4-pyrimodone is in vivo 
mostly recognized as T, C but sometimes also as a G base. 
Although principles like shape recognition (purine-pyrimidine 
base pair formation)  plays a role in the recognition process, it is 
not the only factor involved. The low efficiency of the 
transliteration process of XNA to DNA might implement some 
degree of randomness in the nucleotide selection procedure by 
the incorporated modified (XNA) nucleotide, when pyrimidine 
heterocycles (smaller heterocycles) are involved. 
Experimental Section 
1H, 13C and 31P NMR spectra were recorded on 300 MHz (1H NMR, 300 
MHz; 13C NMR, 75 MHz; 31P NMR, 121 MHz) or 500 MHz (1H NMR, 500 
MHz; 13C  NMR, 125 MHz) or 600 MHz (1H NMR, 600 MHz; 13C  NMR, 150 
MHz) spectrometers. 2D NMRs (H-COSY, HSQC and HMBC) were used 
for the assignment of all the intermediates and final compounds. Mass 
spectra were acquired on a quadrupole orthogonal acceleration time-of-
flight mass spectrometer. Column chromatographic separations were 
carried out by gradient elution with suitable combination of two/three 
solvents and silica gel (100–200 mesh or 230–400 mesh). Solvents for 
reactions were distilled prior to use: THF and toluene from 
Na/benzophenone; CH2Cl2 and CH3CN from CaH2; Et3N and pyridine from 
KOH. 
2-Chloro-4,5-diamino-6-methyl pyrimidine (3). A solution of Na2S2O4 
(28.67 g, 164.6 mmol) in water (78 mL) was added to the stirred solution
of 2 (10.35 g, 54.9 mmol) in THF (274 mL) and ethyl acetate (78 mL) at
room temperature and the reaction was stirred for 3 hours. Ethyl acetate
(200 mL) was added and extracted. The extract was dried over Na2SO4
and concentrated in vacuo. The crude mixture was purified by column
chromatography using DCM:MeOH (9:1, v/v) as solvent to afford 3 (3.42
g, 39%). Analytical data of compound 3 was found to be identical to the
reported compound.[25]
2-Chloro-6-methyl-8-oxo-7,8-dihydro-purine (4).  1,1'-Carbonyl
diimidazole (7.00 g, 43.2 mmol) was added to the solution of 2-chloro- 4,5-
diamine-6-methyl-pyrimidine 3 (3.42 g, 21.6 mmol) in 1,4-dioxane (10 mL)
and stirred at 110 °C under nitrogen for 50 min. Solvents were evaporated 
to obtain a yellow oil and CH2Cl2 (150 mL) was added. The flask shaken
vigorously and allowed to settle the precipitate overnight. Solids were
filtered through sintered funnel, washed with CH2Cl2 and dried under
vacuum at 45 °C to afford 4 (3.29, 83%). 1H NMR (300 MHz, DMSO-d6)
δ 12.00 (br s, 1H, NH), 11.39 (br s, 1H, NH), 2.37 (s, 3H, CH3). 13C NMR
(75 MHz, DMSO-d6) δ 153.7 (C6), 151.9 (C8),149.9 (C2), 144.2 (C4),
120.3 (C5), 18.7 (CH3). HRMS (ESI+): calcd for C6H5ClN4O [M + H]+
185.0224; found 185.0219.
2-Chloro-6-methyl-8-oxo-7,8-dihydro-9-(2-deoxy-α/β-D-erythro-
pentofuranos-1-yl)-purine (6). To a suspension of 4 (3.42 g. 18.5 mmol)
in dry CH3CN (142 mL) was added sodium hydride (60% in oil, 0.489 g,
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20.4 mmol) and the mixture was stirred at room temperature under a 
nitrogen atmosphere for 30 min. 1-Chloro-2-deoxy-3,5-di-O-p-toluoyl-D-
erythro-pentofuranose (7.20 g, 18.5 mmol) was added portion wise with 
stirring. The reaction mixture was stirred at 50 °C for 3 h and filtered to 
remove a small amount of insoluble material. Evaporation of the filtrate 
gave an oily residue, which was purified by silica gel column 
chromatography using ethyl acetate (35%) in hexane to afford nucleoside 
α- and β-5 (3.00 g, 30%). HRMS (ESI+): calcd for C27H25Cl1N4O6 [M + H]+ 
537.1535, found 537.1541.The anomeric mixture (1.50 g, 2.79 mmol) was 
treated with 5 M solution of sodium methoxide (1.05 mL) for 2 h at room 
temperature. The mixture was concentrated and the residue was purified 
by flash column chromatography (CH2Cl2/MeOH 8.5:1.5) to yield the 
anomeric mixture of compound  α- and β-6 as a white solid (0.798 mg, 95 
%). HRMS (ESI+): calcd for C11H13Cl1N4O4 [M + H]+ 301.0698, found 
301.0707. 
2-Chloro-6-methyl-8-oxo-7,8-dihydro-9-(2-deoxy-5-O-dimethoxytrityl-
β-D-erythro-pentofuranos-1-yl)-purine (7). Compound α- and β-6 (320
mg, 1.41 mmol) was co-evaporated with dry pyridine twice under argon
atmosphere and then dissolved in dry pyridine (15 mL). 4,4'–
Dimethoxytrityl chloride (527 mg, 1.56 mmol) in CH2Cl2 (2 mL) was slowly
added drop wise under argon atmosphere at 0 °C, then the mixture was
stirred at room temperature for 2 h. The reaction was quenched by the
addition of MeOH and the solvents were evaporated. The residue was
dissolved in CH2Cl2 and washed with H2O, the organic layers were dried
on Na2SO4 and evaporated under argon atmosphere. The compound 7
was isolated as β anomer by column chromatography separation
(CH2Cl2/MeOH/TEA 97:2:1) as a white foam (372 mg, 58%). 1H and 13C
NMR Spectrum of compound 7 shows that the compounds contain small
amounts of trimethylamine and pyridine as compound stabilizer used
during synthesis and purification. These impurities were removed at the
next step of synthesis. 1H NMR (500 MHz, DMSO-d6) δ 11.87 (s, 1H, NH),
7.38 -7.33 (m, 2H, Ar), 7.22-7.13 (m, 7H, Ar), 6.74 (dd, J = 32.3, 9.0 Hz
4H, Ar), 6.18 (dd, J = 7.6, 5.35 Hz, 1H, H-1’), 5.31 (d, J = 3.0 Hz, OH), 4.45 
(br S, 1H, 3’H), 3.96-3.93 (m, 1H, H-4’), 3.70 (s, 3H, OCH3), 3.69 (s, 3H,
OCH3), 3.29 (dd, J = 10.1, 7.5 Hz, 1H, H-5a’), 3.11 (dd, J = 10.1, 3.8 Hz,
1H, H-5b’), 2.91-2.85 (m, 1H, H-2a’), 2.41 (s, 3H, CH3), 2.19-2.14 (m, 1H,
2b’). 13C NMR (125 MHz, DMSO-d6) δ 148.0, 147.9, 142.2, 140.0, 139.7,
139.6 (C2, C4, C8, C6, Ar), 135.4, 135.1, 126.2, 125.8, 119.8, 119.7,
117.7, 117.6, 116.5, 113.9, 109.37, 102.9, 102.8 (C5, Ar), 75.9 (C4’), 71.1 
(C1’), 61.1 (C3’), 54.6 (C-5’), 45.0, 44.9 (OCH3), 26.1 (C2’), 8.9 (CH3).
HRMS (ESI+): calcd for C32H31ClN4O6 [M + H]+ 603.2004; found 603.2009.
2-Chloro-6-methyl-8-oxo-7,8-dihydro-9-(2-deoxy-β-D-erythro-
pentofuranos-1-yl)-purine (8). Compound 7 (0.431 mmol, 0.26 g) was
dissolved in a mixture of CH2Cl2 and MeOH (1:1 v/v, 25 mL), and HCl in
MeOH (0.14 mL of 1.25 mol L–1 solution) was added portion wise. The
reaction was monitored by TLC CH2Cl2/MeOH(95:5). Once completed, the 
reaction mixture was neutralized with pyridine (1 mL), and the liquid was
concentrated. The resulting oil was purified by column chromatography
CH2Cl2/MeOH (96:4) to afford 8 (54 mg 70%). 1H NMR (500 MHz, MeOD-
d4) δ 6.30 (dd, J = 7.5, 6.9 Hz, 1H, H1’), 4.59-4.57 (m, 1H Hz, H3’), 3.99-
3.96 (m, 1H, H4’), 3.81 (dd, J = 12.1 Hz, 3.8, 1H, H5a’), 3.70 (dd, J = 12.0, 
4.8 Hz, 1H, H5b’), 2.99 (ddd, J = 13.7, 7.5, 6.1 Hz, 1H, 2a’), 2,46 (s, 3H,
CH3), 2.20 (ddd, J = 13.5, 6.7, 3.0 Hz, 1H, H-2b’). 13C NMR (125 MHz,
DMSO-d6) δ 152.7 (C8), 150.5 (C6), 150.2 (C4), 145.9 (C2), 119.3 (C5),
87.7 (C4’), 82.2 (C1’), 71.7 (C3’), 62.5 (C5’), 36.3 (C2’), 17.5 (CH3). HRMS
(ESI+): calcd for C11H13ClN4O4 [M + H]+ 301.0698; found 301.0707.
2-N, N-dimethylformamidine-6-methyl-8-oxo-9-(2’-deoxy-α/β-D-
erythro-pentofuranos-1-yl)-purine 12: To the solution of anomeric
mixture of nucleoside 6 (1.05 gm, 3.49 mmol) in ethanol (10 mL) was
added hydrazine (1.36 mL, 34.92 mmol, 80%). Reaction mixture was
stirred at 84 °C for 12 hrs. The reaction mixture was concentrated and the
crude unstable hydrazine derivative α- and β-9 was used for next reaction 
immediately. To an ice-cold solution of crude compound α- and β-9 (3.49 
mmol) in acetic acid (23 mL) was added dropwise a solution of sodium 
nitrite (53.16 mol) in a least amount of water in an ice bath at −5 °C. The 
reaction mixture was allowed to stir at room temperature for 12 hrs and 
concentrated in vacuo to afford inseparable anomeric mixture of 
nucleoside α- and β-10. To the solution of crude nucleoside α- and β-10 
(3.49 mmol) in methanol was added PtO2 (0.71 mmol) and reaction mixture 
was stirred under hydrogen atmosphere (1.38 bar) at 55 °C for 45 hrs. The 
reaction mixture was filtered through the celite and concentrated under 
vacuo to afford the anomeric mixture of 2-Amino-6-methyl-8-oxo-9-(2’-
deoxy-D-ribofuranosyl)-purine α- and β-11 (X), HRMS (ESI+): calcd for 
C11H15N5O4 [M + H]+  282.1196; found 282.1199.  The crude nucleoside 
α- and β-11 (0.860 mg, 3.06 mmol) was dissolved in methanol (30 mL) and 
dimethylformamide dimethyl acetal (15 ml) was added. Reaction mixture 
was stirred for 1 hour and concentrated on rotary evaporator to afford 
dimethylformamidine protected nucleoside diol α- and β-12, HRMS (ESI+): 
calcd for C14H20N6O4 [M + H]+ 337.1618; found 337.1621. 
2-N,N-dimethylformamidino-6-methyl-8-oxo-7,8-dihydro-9-(2-deoxy-
5-O-dimethoxy trityl-β-D-erythro-pentofuranos-1-yl)-purine (13).
Compound α- and β-12 (444 mg, 1.32 mmol) was co-evaporated with dry
pyridine twice under argon atmosphere and then dissolved in dry pyridine
(26 mL). 4,4'–Dimethoxytrityl chloride (447 mg, 1.35 mmol) in CH2Cl2 (2
mL) was slowly added drop wise under argon atmosphere at 0 °C, then
the mixture was stirred at room temperature for 3 h. The reaction was
quenched by the addition of MeOH and the solvents were evaporated. The 
residue was dissolved in CH2Cl2 and washed with H2O, the organic layers
were dried on Na2SO4 and evaporated under argon atmosphere. The
compound 13 was isolated as beta anomer by column chromatography
(CH2Cl2/MeOH/Pyridine 96:3:1) as a white solid (360 mg, 43%). 1H NMR
(600 MHz, DMSO-d6) δ 11.16 (s, 1H, NH), 8.29 (s, 1H, =CH-N), 7.32-7.31
(m, 2H, Ar), 7.20-7.14 (m, 7H, Ar), 6.77-6.70 (m, 4H, Ar), 6.20 (dd, J = 5.2, 
7.74 Hz, 1H, H1’), 5.24 (d, J = 4.8 Hz,1H, OH), 4.49-4.45 (m, 1H, H3’),
3.89-3.86 (m, 1H, H4’), 3.70 (s, 3H, OCH3), 3.69 (s, 3H, OCH3), 3.25 (dd,
J = 10.0, 7.5 Hz, 1H, H5a’), 3.09 (dd, J = 10.0, 3.54 Hz, 1H, H5b’), 3.00 (s, 
3H, NCH3), 3.01-2.97 (m, 1H, H2a’), 2.96 (s, 3H, NCH3), 2.30 (s, 3H, CH3),
2.11 (ddd, J = 13.2, 8.0, 5.4 Hz 1H, H2b’). 13C NMR (151 MHz, DMSO-d6)
δ 160.4 (C2), 158.0, 157.9 (OCH3), 156.9 (C=N), 152.6 (C8), 149.8 (C4),
145.2 (C6), 144.1, 135.8, 129.8, 129.6,127.8, 127.7, 126.5 (Ar), 114.9
(C5), 113.0, 112.9 (Ar), 85.5 (C-Ar3), 85.3 (C4’), 80.5 (C1’), 71.2 (C3’), 64.8 
(C5’), 55.1, 55.0 (OCH3), 40.3 (C2’), 36.1, 36.4 (NCH3), 19.1 (CH3). HRMS
(ESI+) calcd for C35H38N6O6 [M+H]+ 639.2925 found 639.2927.
2-N, N-dimethylformamidine-6-methyl-8-oxo-9-(2’-deoxy-β-D-erythro -
pentofuranos-1-yl)-purine (β-12): The column of silica gel (10.0 g) was
first prepared in dichloromethane containing 1% pyridine. This column was 
overlayed with a small buffer of sand followed by more silica gel (3.0 g) in
dichloromethane containing 1% TFA. The compound 13 (100 mg) was
then loaded in 3 mL of CH2Cl2. The column was eluted with gradient
solvent system CH2Cl2/MeOH/Pyridine. The compound β-12 was eluted
with CH2Cl2/MeOH/Pyridine (96:3:1). 1H NMR (500 MHz, DMSO-d6) δ
11.35 (s, 1H, NH), 8.54 (s, 1H, =CH-N), 6.18 (t, J = 7.4 Hz, 1H, H1’), 5.22
(d, J = 4.0 Hz,1H, OH), 4.89 (t, J = 7.4 Hz, 1H, OH), 4.42 (d, J = 2.7 Hz,
1H, H3’), 3.79 (dd, J = 7.4, 4.65 Hz, 1H, H4’), 3.60 (dt, J = 11.9, 4.0 Hz,
1H, H5b’), 3.49-3.44 (m, 1H, H5a’), 3.15 (s, 3H, NCH3), 3.03 (s, 3H, NCH3),
3.03-2.97 (m, 1H, H2a’), 2.34 (s, 3H, CH3), 2.01 (ddd, J = 13.0, 6.7, 2.9
Hz, 1H, H2b’). 13C NMR (125 MHz, DMSO-d6) δ 158.4 (C=N), 154.3 (C6,
C2), 151.8 (C8), 145.9 (C4), 117.1 (C5), 89.4 (C4’), 83.0 (C1’), 73.1 (C3’),
64.2 (C5’), 42.8 (NCH3) 37.6 (C2’), 36.8 (NCH3), 20.8 (CH3). HRMS (ESI+) 
calcd for C14H20N6O4 [M+H]+ 337.1618, found 337.1617.
3’-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite of 2-N,N-dimethyl 
formamimidino-6-methyl-8-oxo-7,8-dihydro-9-(2-deoxy-5-O-
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dimethoxytrityl-β-D-erythro-pentofuranos-1-yl)-purine (14). To a 
stirred solution of 13 (350 mg, 1.41 mmol) and 1 M solution of 
bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.32 mL, 1.32 mmol) in 
anhydrous CH2Cl2 (10 mL), under argon atmosphere and at 0 °C, was 
added 0.45 M solution of 1H-terazole (1.62 mL, 0.728 mmol) dropwise. 
After 10 min, the ice bath was removed and reaction mixture was allowed 
to stir at room temperature for 45 min. The reaction mixture was diluted 
with CH2Cl2 and was washed with 1M TEAB solution. The extracts were 
dried over Na2SO4 and concentrated in vacuo. The crude mixture was 
purified by flash column chromatography (Hexane/Acetone/TEA, 80:20:1) 
to afford amidite 14 (300 mg, 62% yield). 31P NMR (121 MHz, DMSO-d6) 
δ 147.79, 147.41; HRMS (ESI+) calcd for C44H55N8O7P1 [M+H]+ 839.4003, 
found 839.4009. 
2-Amino-6-methyl-8-oxo-7,8-dihydro 8-9-(2-deoxy-5-O-triphosphate-
β-D-erythro-pento-furanos-1-yl-purine (15). To an ice-cold solution of
protected nucleoside β-12 (30 mg, 0.09 mmol) in trimethyl phosphate
(TMP) (1.0 mL) was added phosphoryl chloride (12 µL, 0.13 mmol.) and
the solution stirred at 0°C for 5 hours. Tributylamine (105 µL, 0.44 mmol)
and tetrabutylammonium pyrophosphate solution (240 mg, 0.27 mmol) in
DMF (1 mL) was added simultaneously, and the solution stirred for a
further 30 minutes. The reaction was then quenched by the addition of 0.5 
M triethylammonium bicarbonate (TEAB) buffer (10 mL), and stored at 4°C 
overnight. The solvent was evaporated and the residue was treated with
25% ammonia (1 mL) for 15 min. The solution was evaporated to dryness
and re-dissolved in water (5 mL) and applied to a Sephadex A25 column
in 0.1 M TEAB buffer. The column was eluted with a linear gradient of 0.1-
1.0 M TEAB. Appropriate fractions were pooled and evaporated to dryness 
to give desired product. The final purification was performed by RP HPLC
(Alltima 5µ C-18 reverse phase column, buffer A, 0.1 M TEAB; buffer B,
0.1 M TEAB, 50% MeCN. 0% to 100% buffer B over 60 min). 31P NMR
(D2O, δ, ppm): -6.38 (1P-γ, d, J 20 Hz), -11.91 (1P-α, d, J 20 Hz), -22.64
(1P-β, t, J 20 Hz). ESIHRMS found: (M-H)– 520.0041. calcd for
C11H18N5O13P3: (M-H)– 520.0041.
6-Methyl-3-(2-deoxy-β-D-erythro-pentofuranos-1-yl)-4(3H)-
pyrimidone (Z). To a stirred solution of 6-methyl-4-pyrimidone (637 mg,
5.79 mmol) in acetonitrile (25 mL) at room temperature under argon was
added bis(trimethylsilyl)acetamide (1.18 g, 5.79 mmol). After stirring at
ambient temperature for 40 min, 1-chloro-2-deoxy-3,5-di-O-p-toluoyl-D-
erythro-pentofuranose (1.5 g, 3.86 mmol) and dropwise SnCl4 (3.87 mL,
3.86 mmol) was added. After 1 h, complete dissolution of the 2-
deoxyribofuranoside had occurred. To the reaction was added EtOAc, and 
the resulting solution was successively extracted with saturated NaHCO3
and brine. The organics were dried over anhydrous Na2SO4, and solvents
were removed in vacuo. Purification via flash column chromatography on
silica gel (30-50% ethyl acetate in hexanes) afforded a mixture of two
anomers. The anomeric mixture was treated with 5 M solution of sodium
methoxide (0.650 mL) for 2 h at room temperature. The mixture was
concentrated and the residue was purified by flash column
chromatography (CH2Cl2/MeOH 8.5:1.5) to yield the title compound Z as a
white solid (315 mg, 36 %). 1H NMR (600 MHz, DMSO-d6) δ 8.63 (s,
1H, H2), 6.25 – 6.11 (m, 2H, H5,H1’), 5.27 (d, J = 4.2 Hz, 1H, OH),
5.07 (t, J = 5.1 Hz, 1H, OH), 4.27 (dq, J = 7.5, 3.8 Hz, 1H, H3’), 3.87
(q, J = 3.6 Hz, 1H, H4’), 3.64 (ddd, J = 11.9, 5.0, 3.7 Hz, 1H, H5b’),
3.57 (ddd, J = 11.9, 4.7, 4.1 Hz, 1H, H5a’), 2.29 (ddd, J = 13.3, 6.2,
3.8 Hz, 1H, H2b’), 2.19 (s, 3H, CH3), 2.12 – 2.08 (m, 1H, H2a’); 13C
NMR (151 MHz, DMSO-d6) δ l163.4 (C4), 159.9 (C6), 147.7 (C2),
111.3 (C5), 88.0 (C4’), 84.4 (C1’), 70.1 (C3’), 60.9 (C5’), 41.1 (C2’),
23.1(CH3); HRMS (ESI+) calcd for C10H14N2O4 [M+Na]+ 249.0846,
found 249.0847.
Further elution with (CH2Cl2/MeOH 8:2) afforded alpha isomer of 
compound Z as a white solid (157 mg, 18 %). 1H NMR (500 MHz, 
DMSO-d6) δ 8.41 (s, 1H, H2), 6.19 (s, 1H, H5), 6.16 (d, J = 5.9 Hz, 
1H, H1’), 4.31 (t, J = 4.3 Hz, 1H, H4’), 4.25 (d, J = 5.5 Hz, 1H, H3’), 
3.49 – 3.36 (m, 2H, H5), 2.61 – 2.53 (m, 1H, H2b’), 2.18 (s, 3H, CH3), 
1.95 (d, J = 14.2 Hz, 1H, H2a’); 13C NMR (126 MHz, DMSO) δ 163.7 
(C4), 160.4 (C6), 148.1 (C2), 111.6 (C5), 90.6 (C4’), 86.8 (C1’), 71.1 
(C3’), 62.4 (C5’), 41.0 (C2’), 23.4 (CH3); HRMS (ESI+) calcd for 
C10H14N2O4 [M+Na]+ 249.08460, found 249.0853. 
6-Methyl-3-(2-deoxy-5-O-dimethoxytrityl- β-D-erythro-pentofuranos-
1-yl)-4(3H)-pyrimidone (16). Compound Z (320 mg, 1.41 mmol) was co-
evaporated with dry pyridine (2 x 10 mL) under argon atmosphere and then 
dissolved in dry pyridine (15 mL). 4,4'–Dimethoxytrityl chloride (527 mg,
1.56 mmol) in CH2Cl2 (2 mL) was slowly added drop wise under argon
atmosphere at 0 °C, then the mixture was stirred at room temperature for
2 h. The reaction was quenched by the addition of MeOH and the solvents 
were evaporated. The residue was dissolved in CH2Cl2 and washed with
H2O, the organic layers were dried on Na2SO4 and evaporated under
argon atmosphere. Compound 16 was isolated by column
chromatography (CH2Cl2/MeOH/TEA 97:2:1) as a white solid (520 mg,
69%). 1H NMR (500 MHz, DMSO-d6) δ 8.40 (s, 1H, H2), 7.38 (d, J = 7.4
Hz, 2H, Ar), 7.33 – 7.19 (m, 7H, Ar), 6.88 (d, J = 8.4 Hz, 4H, Ar), 6.27 –
6.22 (m, 2H, H1’, H5), 5.34 (d, J = 4.6 Hz, 1H, OH), 4.26 (dq, J = 9.0, 4.5
Hz, 1H, H3’), 3.99 (dd, J = 8.3, 4.5 Hz, 1H, H4’), 3.74 (s, 6H, 2CH3), 3.24
(dd, J = 10.5, 5.5 Hz, 1H, H5’b), 3.20 (dd, J = 10.5, 3.1 Hz, 1H, H5’a), 2.34
(ddd, J = 13.4, 6.5, 4.5 Hz, 1H, H2b’), 2.22 (dd, J = 13.3, 6.6 Hz, 1H, H2a’), 
2.18 (s, 3H, CH3); 13C NMR (126 MHz, DMSO-d6) δ 163.5 (C4), 159.8,
158.1 (C6, Ar), 147.3 (C2), 144.8, 135.5, 135.4, 129.8, 127.9, 127.7, 126.8 
(Ar), 113.3 (Ar), 111.6 (C5), 86.0 (C4’), 85.8 (C), 84.6 C1’), 70.2 (C3’), 63.6 
(C5’), 55.0 (CH3), 40.7 (C2’), 23.1 (CH3); HRMS (ESI+) calcd for
C31H32N2O6 [M+Na]+ 551.2152, found 551.2151.
The 3’-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite of 6-methyl-
3’-(2-deoxy-5-O-dimethoxytrityl-β-D-erythro-pentofuranos-1-yl)-
4(3H)-pyrimidone (17). To a stirred solution of 16 (350 mg, 1.41 mmol) 
and 1 M solution of bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.32 
mL, 1.32 mmol) in anhydrous CH2Cl2 (10 mL), under argon atmosphere 
and at 0 °C, was added 0.45 M solution of 1H-terazole (1.62 mL, 0.728 
mmol) dropwise. After 10 min, the ice bath was removed and reaction 
mixture was allowed to stir at room temperature for 45 min. The reaction 
mixture was diluted with CH2Cl2 and was washed with 1M TEAB solution. 
The extracts were dried over Na2SO4 and concentrated in vacuo. The 
crude mixture was purified by flash column chromatography 
(Hexane/Acetone/TEA, 80:20:1) to afford amidite 17 (300 mg, 62% yield). 
31P NMR (121 MHz, DMSO-d6) δ 147.75, 147.37; HRMS (ESI+) calcd for 
C40H49N4O7P [M+Na]+ 751.3231, found 751.3222. 
2-Methyl-6-chloro-9-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythro-
pentofuranos-1-yl)-purine (18a). A mixture of 6-chloro-2-methylpurine[26]
(520 mg, 3.09 mmol) and 60% sodium hydride (164 mg, 4.11 mmol) in
anhydrous acetonitrile (15 mL) was stirred at ambient temperature for 30
minutes under a nitrogen atmosphere. The 1-chloro-2-deoxy-3,5-di-O-p-
toluoyl-D-erythro-pentofuranose (800 mg, 2.06 mmol) was added
portionwise, and stirred for 2 hours. The reaction mixture was diluted with
ethylacetate and washed with water. The organics were dried over
anhydrous Na2SO4, and solvents were removed in vacuo. Purification via
column chromatography on silica gel (30% ethyl acetate in hexanes)
afforded the desired product 18a as a white solid compound (815 mg,
76%). 1H NMR (600 MHz, CDCl3) δ 8.41(s, 1H, H8), 7.96 (d, J = 8.0 Hz,
2H, Ar-H), 7.54 (d, J = 8.0 Hz, 2H, Ar-H), 7.29-7.25 (m, 2H, Ar-H), 7.20-
7.16 (m, 2H, Ar-H), 6.64 (d, J = 6.6 Hz, 1H, H1’), 5.71 (d, J = 6.4 Hz, 1H,
H3’), 4.91 (br S, 1H, H4’), 4.66-4.59 (m, 2H, H5’), 3.20 (d,  J = 15.0 Hz,
1H, H2b’), 3.04 (dt, J = 15.0, 6.6 Hz, 1H, H2a’), 2.72 (s, 3H, CH3), 2.43 (s,
3H, CH3), 2.39 (s, 3H, CH3); 13C NMR (151 MHz, CDCl3) δ 166.1, 165.7
(C=O), 162.5 (C2), 151.5 (C4), 150.4 (C6), 144.7, 144.3 (Ar), 142.5 (C8),
Ac
ce
pt
ed
 A
rti
cl
e
10.1002/chem.201802304
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
FULL PAPER 
129.8, 129.6, 129.3, 129.3 (Ar, C5), 126.6, 125.7 (Ar), 86.3 (C1’), 84.7 
(C4’), 74.8 (C3’), 63.9 (C5’), 38.3 (C2’), 25.6 (CH3), 21.7 (CH3), 21.6 (CH3); 
HRMS (ESI+) calcd for C27H25ClN4O5 [M+Na]+ 543.1405, found 543.1409 
2-Methyl-6-sulfhydryl-9-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythro-
pentofuranos-1-yl)-purine (18b): To a solution of compound 18a (750
mg, 1.4 mmol) in 1:1-ethanol and water (40 mL), sodium thiosulfate (1.14
g, 7.2 mmol) was added and heated at 120 °C in a seal tube for 12 hours.
The reaction mixture was concentrated and diluted with ethyl acetate and
washed with water. The organics were dried over anhydrous Na2SO4, and
solvents were removed in vacuo. Purification via column chromatography
on silica gel (50% ethyl acetate in hexanes) afforded the desired product
18b as a white solid compound (600 mg, 80%). 1H NMR (600 MHz, DMSO-
d6) δ 8.41 (s, 1H, H8), 7.93 (d, J =8.2 Hz, 2H, Ar-H), 7.81 (d, J =8.2 Hz,
2H, Ar-H), 7.36 (d, J =8.2 Hz, 2H, Ar-H), 7.29 (d, J =8.2 Hz, 2H, Ar-H), 6.46 
(t, J =7.1 Hz, 1H, H1’), 5.80-5.76 (m, 1H, H3’), 4.64 (dd, J = 10.8, 4.2 Hz,
H5b’), 4.58-4.52 (m, 2H, H5a’, H4’), 3.21-3.16 (m, 1H, H2b’), 2.77 (ddd, J
= 9.3, 6.7, 2.9 Hz, 1H, H2a’), 2.47 (s, 3H, CH3), 2.39 (s, 3H, CH3), 2.36 (s,
3H, CH3); 13C NMR (151 MHz, DMSO-d6) δ 176.8 (C6), 165.5, 165.3
(C=O), 155.4 (C2), 144.2, 144.1, 143.9 (Ar-C, C4), 140.9 (C8), 133.9 (C5), 
129.5, 129.4, , 129.3, 126.6, 126.5 (Ar-C), 83.8 (C1’), 81.8 (C4’), 74.8
(C3’), 63.9 (C5’), 35.8 (C2’), 21.3 (CH3), 21.2 (CH3), 21.0 (CH3); HRMS
(ESI+) calcd for C27H26N4O5S [M+H]+ 519.1696, found 519.1700.
2-Methyl-6-sulfhydryl-9-(2-deoxy-β-D-erythro-pentofuranos-1-yl)-
purine (Y). 5 M solution of sodim methoxide (0.25 mL) solution was added 
to compound 18b (650 mg, 1.25 mmol) and the mixture was stirred for 1.5
h at room temperature. The reaction mixture was concentrated and the
residue was purified by flash column chromatography (CH2Cl2/MeOH 9:1)
to yield the title compound Y as a white solid (276 mg, 78%). 1H NMR (600
MHz, DMSO-d6) δ 8.41(s, 1H, H8), 6.28 (dd, J = 7.1, 4.0 Hz, 1H, H1’), 5.32 
(d, J = 4.0 Hz, 1H, OH), 4.98 (t, J = 5.5 Hz, 1H, OH), 4.40-4.35 (m, 1H,
H3’), 3.87- 3.83 (m, 1H, H4’), 3.59 (dt, J = 9.9, 4.8 Hz, 1H, H5a’), 3.53-3.48
( m, 1H, H5b’), 2.63- 2.56 (m, 1H, H2b’), 2.49 (s, 3H, CH3), 2.28 (ddd, J =
9.9, 6.1, 3.3 Hz, 1H, H2a’); 13C NMR (151 MHz, DMSO-d6) δ 176.6 (C6),
155.3 (C2), 144.2 (C4), 140.7 (C8), 133.6 (C5), 88.1 (C1’), 83.5 (C4’), 70.7
(C3’), 61.6 (C5’), 48.7 (C2’), 21.0 (CH3); HRMS (ESI+) calcd for
C11H14N4O3S [M+H]+ 283.0859, found 283.0863.
2-Methyl-6-cyanoethylthio-9-(2-deoxy-β-D-erythro-pentofuranos-1-
yl)-purine (19). To a solution of dry compound Z (25 mg, 0.88 mmol) in
dry DMF (6 mL) was added powdered anhydrous potassium carbonate
(474 mg, 3.54 mmol). This was followed by the addition of 3-
bromopropionitrile (367 mg, 2.66 mmol) via a dry syringe. After stirring at
room temperature for 12 hours the DMF was removed by coevaporation
with xylenes and the residue was purified by flash column chromatography 
(CH2Cl2/MeOH 95:5) to yield the title compound 19 as a white solid (240
mg, 80%). 1H NMR (500 MHz, DMSO-d6) δ 8.60 (s, 1H, H8), 6.41 (t, J =
7.1 Hz, 1H, H1’), 5.34 (d, J = 3.9 Hz, 1H, OH), 5.05 (t,  J  = 5.6 Hz, 1H,
OH), 4.43 (br s, 1H, H3’), 3.89 (d, J  = 2.7 Hz, 1H, H4’), 3.64-3.51 (m, 4H,
SCH2, H5’), 3.06-3.02 (t, J  = 6.6 Hz, 2H, CH2), 2.75-2.68 ( m, 1H, H2a’),
2.64 (s, 3H, CH3), 2.34-2.30 (m, 1H, H2b’); 13C NMR (126 MHz, DMSO-
d6) δ 160.7, 157.5 (C2, C6), 148.9 (C4), 142.8 (C8), 129.3 (C5), 119.3
(CN), 88.1 (C4’), 83.8 (C1’), 70.8 (C3’), 61.7 (C5’), 39.5 (C2’), 25.6 (CH3),
23.6 (CH2S), 18.0 (CH2CN); HRMS (ESI+) calcd for C14H17N5O3S [M+H]+
336.1124, found 336.1134.
2-Methyl-6-cyanoethylthio-9-(2-deoxy-5-O-dimethoxytrityl-β-D-
erythro-pentofuranos-1-yl)-purine (20). The reaction of compound 19
(220 mg, 0.62 mmol) in dry pyridine (13 mL) and 4,4'–dimethoxytrityl
chloride (233 mg, 0.69 mmol) was carried out as described for compound
16 and purified by flash column chromatography (CH2Cl2/MeOH/TEA
97:2:1), affording compound 20 as a white solid (261 mg, 75%); 1H NMR
(600 MHz, DMSO-d6) δ 8.50 (s, 1H, H8), 7.31-7.29 (m, 2H, ArH), 7.24 –
7.13 (m, 7H, ArH), 6.79 – 6.72 (m, 4H, ArH), 6.43 (t, J = 6.4 Hz, 1H, H1’), 
5.39 (d, J = 4.6 Hz, 1H, OH), 4.49-4.45 (m, 1H, H3’), 4.01 (dt, J = 6.8, 4.0 
Hz, 1H, H4’), 3.71 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 3.60 (t, J = 6.8 Hz, 
2H, SCH2), 3.26 (dd, J = 10.1, 6.7 Hz, 1H, H5b’), 3.16 (dd, J = 10.1, 3.8 
Hz, 1H, H5a’), 3.04 (t, J = 6.7 Hz, 2H, CH2CN), 2.88 (dt, J = 12.8, 6.2 Hz, 
1H, H2b’), 2.50 (s, 3H, CH3), 2.35-2.37 (m, 1H, H2a’); 13C NMR (151 MHz, 
DMSO-d6) δ 160.7 (C2), 158.1, 158.0, 157.4 (C6, Ar), 148.9 (C4), 144.9 
(Ar), 143.2 (C8), 135.6, 135.5 (Ar), 129.7, 129.6, 129.5, 127.7, 127.6, 
126.6 (Ar, C5), 119.3 (CN), 113.1, 113.0 (Ar), 86.2 (C4’), 85.4 (C), 83.9 
(C1’), 70.8 (C3’), 64.2 (C5’), 55.1, 55.0 (OCH3), 38.4 (C2’), 25.6 (CH3), 
23.7 (CH2), 18.0 (CH2). HRMS (ESI+) calcd for C35H35N5O5S [M+H]+ 
638.2431, found 638.2446.  
The 3’-(2-cyanoethyl-N,N-diisopropyl)phosphoramidite of 2-methyl-
6-cyanoethylthio-9-((2-deoxy-5-O-dimethoxytrityl-β-D-erythro-
pentofuranos-1-yl)-purine (21). The reaction of compound 20 (250 mg,
0.39 mmol) and 1 M bis(diisopropylamino)(2-cyanoethoxy)phosphine (784 
μl, 0.78 mmol) and 0.45 M 1H-terazole (958 μl, 0.431 mmol) in anhydrous
CH2Cl2 (8 mL), was carried out as described for compound 21 and purified 
by flash column chromatography (CH2Cl2/MeOH/TEA 98:1:1) afforded
amidite 21 (223 mg, 68% yield); 31P NMR (202 MHz, DMSO-d6) δ 147.86,
147.22; HRMS (ESI+) calcd for C44H52N7O6PS [M+H]+ 838.3509, found
838.3516.
Oligonucleotide synthesis. 
Oligonucleotide assembly was performed with an Expedite DNA 
synthesizer (Applied Biosystems) by using the phosphoramidite approach. 
The oligomers were deprotected and cleaved from the solid support by 
treatment with aqueous ammonia (30%) for 1/2 h at 25 °C and 1 h at 55 °C. 
After gel filtration on a NAP-25 column (Sephadex G25-DNA grade from 
GE Healthcare) with water as eluent, the crude mixture was analyzed by 
using a Mono-Q HR 5/5 anion exchange column, after which purification 
was achieved by using a Mono-Q HR 10/100 GL column (Pharmacia) with 
the following gradient system: Buffer A = 10 mM NaClO4 with 20 mM Tris-
HCl in 15% CH3CN, pH = 7,4. Buffer B = 600 mM NaClO4 with 20 mM Tris-
HCl in 15% CH3CN, pH=7,4. The low-pressure liquid chromatography 
system consisted of a HITACHI Primaide organizer with a HITACHI 
Primaide 1410 UV detector and with a HITACHI Primaide 1110 pump and 
a Mono-Q HR 10/100 GL column (Pharmacia). The product-containing 
fraction was desalted on a NAP-25 column and lyophilised, followed by 
analysis by mass spectrometry. 
UV melting experiments. 
Oligomers were dissolved in a buffer solution containing NaCl (0.1 M), 
KH2PO4 (0.02 M, pH 7,5) and EDTA (0.1 mM). The concentration was 
determined by measuring the absorbance in Milli-Q water at 260 nm at 
80°C. The following extinction coefficients were used: dA, ε=15.060; dC, 
ε=7.100; dG, ε=12.180; dT, ε=8.560; X, ε= 2089; Y, ε = 903; Z, ε = 2919. 
Extinction coefficient have been determined at 260 nm, which is not the 
maximum of absorption, but the wavelength at which the concentration of 
the oligonucleotide is determined. The concentration for each strand was 
4 µM in all experiments. Melting curves were determined with a Varian 
Cary 100 BIO spectrophotometer. Cuvettes were maintained at constant 
temperature by water circulation through the cuvette holder. The 
temperature of the solution was measured with a thermistor that was 
directly immersed in the cuvette. Temperature control and data acquisition 
were carried out automatically with an IBM-compatible computer by using 
Cary WinUV thermal application software. A quick heating and cooling 
cycle was carried out to allow proper annealing of both strands. The 
samples were then heated from 10 to 80 °C at a rate of 0.2 °C min-1, and 
were cooled again at the same speed. Melting temperatures were 
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determined by plotting the first derivative of the absorbance as a function 
of temperature; data plotted were the average of two runs. Up and down 
curves showed identical Tm values. 
Circular dichroism materials and methods. 
For CD analysis, 4 µM of modified duplex [5’-d (CAC CGX/Y TGC TAC C)-
3’ and 5’-d (GGT AGC AX/Y C GGT G)-3’)] and natural duplex [5’-d (CAC 
CGA TGC TAC C)-3’ and 5’-d (GGT AGC ATC GGT G)-3’) ] were dissolved 
in buffer (0.1 M  NaCl, 20 mM KH2PO4 and 0.1 mM EDTA) at pH 7. CD 
experiments were performed with Jasco J-1500 spectropolarimeter 
equipped with a Julabo F12 Peltier thermoelectric temperature control unit. 
Spectra were recorded at 25 °C using a 1 mm path length quartz cuvette 
with scanning from 320 to 200 nm. Three scans were averaged with a 
bandwidth of 1 nm and a 0.5 s averaging time at a rate of 50 nm/min. 
Primer extension experiments by DNA polymerases. 
The incorporation of natural dNTPs and the 2-amino-6-Methyl-8-oxo-7,8-
dihydro-purine nucleoside triphosphate was carried out using a Cy5 
fluorescence labeled primer and a template containing one or three 2-
amino-6-methyl-8-oxo-7,8-dihydro-purine nucleosides, incorporated (ON 
28, 29). The primer 5’Cy5-CAGGAAACAGCTATGAC-3’ was annealed 
with one of the templates 5’-AACTGXGTCATAGCTGTTTCCTG-3’ or 5’-
AACTGXXXGTCATAGCTGTTTCCTG-3’ in a 1:2 molar ratio by heating 
the mixture at 95 °C for 5 minutes followed by slow cooling to room 
temperature. A mesophilic DNA polymerase: Klenow fragment exo- (New 
England Biolabs) and a thermostable polymerase Pol6G12[27] were used. 
The final DNA polymerization mixtures each contained 125 nM primer-
template duplex, reaction buffer (NEBuffer 2 was used for Klenow 
fragment exo- and ThermoPol buffer was used for Pol6G12) and 50 µM of 
the natural dNTPs or 50 µM or 200 µM of 2-amino-6-Methyl-8-oxo-7,8-
dihydro-purine nucleoside triphosphate. Final concentration in a reaction 
of Klenow fragment exo- and Pol6G12 were 0.0017 U/µl and 0.0186 U/µl, 
respectively. One millimolar of MnCl2 was added in the reaction as 
indicated. The reactions were performed at 37 °C for Klenow fragment exo- 
and 75 °C for Pol6G12. Aliquotes were taken after 60 min and quenched 
by adding to a double volume of quenching buffer (90 % formamide, 50 
mM EDTA, and 0.05 % bromophenol blue) and heated at 95 °C for 5 min. 
The samples were separated on a 1 mm 15 % denaturing polyacrylamide 
gel and gel bands were visualized using the Typhoon FLA 9500 phosphor 
imager (GE Healthcare Life Sciences). The images were processed using 
ImageQuant TL v8.1.0.0 (GE Healthcare). 
In vivo transliteration and mutational analysis directed by 
modified oligonucleotides ligated to plasmid DNA. 
Oligonucleotides were dissolved in milliQ water to 1 mM and diluted ten 
fold before assay. Oligonucleotides were tested inside a gapped 
heteroduplex generated through the enzymatic modification of two 
different plasmids pAK1 and pAK2. The form of the heteroduplex is 
described elsewhere in details (S. Pochet, C. R. Biologies, 2003 and Pezo, 
Angew. Chem., 2013). [3a, 3c] A mix of equimolar (25 ng each) purified NheI 
and NsiI cut pAK1 and purified EcoRI cut and dephosphorylated pAK2 
were resuspended in 10 mM Tris-HCl pH 7.5 with 100 mM NaCl in 20 μL 
final volume. The mixture was denaturated at 95 °C for 5 min before 
cooling to ambient temperature over 2 h for hybridization, before water 
dialysis through 0.05 μM nitrocellulose filter (Millipore) for 30 min. The 
oligonucleotides (100 pmoles), as well as a positive control (olignucleotide 
with intact catalytic residue codon) and two negative controls (water and 
oligomer with deleted catalytic residue codon) were added separately to 
the dialyzed heteroduplex mixture in 1x DNA ligase T4 reaction buffer 
(NEB) for 20 μL per sample. The mixture was then denaturated at 85 °C 
and cooled as before. Ligation was performed by adding 1 mM ATP and 5 
U T4 DNA ligase (NEB) to the samples before overnight incubation at 16 
°C. Ligated mixtures were dialyzed as before, and transformed by 
electroporation into fresh electro-competent E. coli K12 strain (ΔthyA:aad). 
Incubation of the electroporated bacteria was performed at 37 °C for 1 
hour, before plating 100 μL of a serial dilution of the suspension onto 
Muller-Hinton (MH) media containing 100 μg mL-1 ampicillin (spreading the 
100 and 10-1 dilutions) and onto the same media supplemented additionally 
with 0.3 mM thymidine (10-3 and 10-4 dilutions). 
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